252 related articles for article (PubMed ID: 23434337)
1. New drugs for children and adolescents with cancer: the need for novel development pathways.
Vassal G; Zwaan CM; Ashley D; Le Deley MC; Hargrave D; Blanc P; Adamson PC
Lancet Oncol; 2013 Mar; 14(3):e117-24. PubMed ID: 23434337
[TBL] [Abstract][Full Text] [Related]
2. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
3. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
4. Public-private partnership models in France and in Europe.
Demotes-Mainard J; Canet E; Segard L
Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
7. New policies to address the global burden of childhood cancers.
Sullivan R; Kowalczyk JR; Agarwal B; Ladenstein R; Fitzgerald E; Barr R; Steliarova-Foucher E; Magrath I; Howard SC; Kruger M; Valsecchi MG; Biondi A; Grundy P; Smith MA; Adamson P; Vassal G; Pritchard-Jones K
Lancet Oncol; 2013 Mar; 14(3):e125-35. PubMed ID: 23434339
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
Vassal G; Méry-Mignard D; Caulin C
Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
[TBL] [Abstract][Full Text] [Related]
9. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Challenges in prescribing drugs for children with cancer.
Paolucci P; Jones KP; del Carmen Cano Garcinuno M; Catapano M; Iolascon A; Ceci A
Lancet Oncol; 2008 Feb; 9(2):176-83. PubMed ID: 18237852
[TBL] [Abstract][Full Text] [Related]
12. Into the valley of death: research to innovation.
Hudson J; Khazragui HF
Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
[TBL] [Abstract][Full Text] [Related]
13. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
14. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
15. The PCAST report on pharmaceutical innovation: implications for the FDA.
Woodcock J
Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215
[TBL] [Abstract][Full Text] [Related]
16. Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?
Moreno L; Pearson AD
Expert Rev Clin Pharmacol; 2015; 8(6):665-7. PubMed ID: 26307367
[TBL] [Abstract][Full Text] [Related]
17. Developing paediatric medicines: identifying the needs and recognizing the challenges.
Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
[TBL] [Abstract][Full Text] [Related]
18. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
Smith MA; Anderson BD
Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
[TBL] [Abstract][Full Text] [Related]
19. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
[TBL] [Abstract][Full Text] [Related]
20. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
